1Richard M G,Neal J M,Josep Tabernero,et al.Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer[J].Gastrointest Cancer,2009,3(suppl 2):S23-S27.
2Hanna K S,Richard M G.Colorectal cancer treatment in older patients[J].Gastrointestinal cancer research,2007,1:248-253.
3Underhill C,Goldstein D,Gorbounova VA,et al.A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer[J].Oncology.2007,73(1-2):9-20.
4Atkins JN,Jacobs SA,Wieand HS,et al.Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer:a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program[J].Clin Colorectal Cancer.2005 Sep,5(3):181-187.
5John W,Picus J,Blanke CD,et al.Activity of multitargeted antifolate (pemetrexed disodium,LY231514) in patients with advanced colorectal carcinoma:results from a phase II study[J].Cancer.2000 Apr 15;88(8):1807-1813.
6Hochster H,Kettner E,Kroning H,et al.Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancer[J].Clin Colorectal Cancer.2005 Nov;5(4):257-562.
8Souglakos J,Androulakis N,Syrigos K,et al.FOLFOXIRI(folinic acid,5-fluorouracil,oxaliplatin and irinotecan) VS FOLFIRI (foiinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre andomised phase Ⅲtrial from the Hellenic Oncology Research Group (HORG)[J].Br J Cancer,2006,94 (6):798-805.
9VareyAH,Rennel ES,Qiu Y,et al.VEGF 165 b,an antiangiogenic VEGF2A isoform,binds and inhibits bevacizumab treatment in experimental colorectal carcinoma:balance of pro-and antiangiogenic VEGF2A isoforms has implications for therapy[J].BrJ Cancer,2008,98:1366-1379.
10van Krieken H,Tol J.Setting future standards for KRAS testing in colorectal cancer[J].Pharmacogenomics,2009,10:1-3.
二级参考文献14
1Richard M G, Neal J M, Josep Tabernero, et al. Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer [J]. Gastrointest Cancer, 2009, 3(suppl 2):S23-S27.
2Hanna K S, Richard M G. Colorectal cancer treatment in older patients[J]. Gastrointestinal cancer research, 2007, 1 : 248- 253.
3British Colorectal Collaborative Group. Surgery for eolorectal cancer in elderly patients: a systematic review[J]. Lancet, 2000,356 (9234) : 968- 974.
4MeCardle C S, Hole D J. Outcome following surgery for colorectal cancer[J]. Br Med Bull, 2002,64:119-125.
5Lacy A M, Garcia--Valdecasas J C, Delgado S,et al. Laparoscopy -assisted colectomy versus colectomy for treatment of non-metastatic colon cancer: a randomized trial[J]. Lancet, 2002,359:2224-2229.
6Andre T, Boni C, Navarro M, et al. Improved overall survival with oxalipatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial[J]. J Clin, 2009, 27: 3109-3116.
7Twelves C. Capecitabine as adjuvant treatment for stage Ⅲ colon cancer[J]. N Engl J Med, 2005,352: 2696-2704.
8Schrag D, Cramer L D,Bach P B, et al. Age and adjuvant chemotherapy use after surgery for stage Ⅲ colon cancer[J]. J Natl Cancer Inst, 2001,93: 850-857.
9Daniel J S, Richard M G, Stacy D J, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients [J]. N Engl Med,2001, 345(15):1091-1097.
10Folprecht G, Seymour M T, Saltz L, et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials[J]. J Clin Oncol, 2008,26: 1443-1451.
